Premium
A Telomerase‐Specific Doxorubicin‐Releasing Molecular Beacon for Cancer Theranostics
Author(s) -
Ma Yi,
Wang Zhaohui,
Zhang Min,
Han Zhihao,
Chen Dan,
Zhu Qiuyun,
Gao Weidong,
Qian Zhiyu,
Gu Yueqing
Publication year - 2016
Publication title -
angewandte chemie
Language(s) - English
Resource type - Journals
eISSN - 1521-3757
pISSN - 0044-8249
DOI - 10.1002/ange.201509182
Subject(s) - telomerase , doxorubicin , molecular beacon , chemistry , telomere , dna , cancer cell , drug delivery , microbiology and biotechnology , cancer , cancer research , biology , biochemistry , chemotherapy , oligonucleotide , gene , genetics , organic chemistry
A molecular beacon‐based drug delivery system was designed for both detection of telomerase activity in living cells and telomerase‐triggered drug release for precise cancer treatment. This system is composed of a gold nanoparticle core densely packed with FITC‐labeled hairpin DNA sequences hybridized with telomerase primers. Molecules of the anticancer drug doxorubicin were intercalated into the stem region of the DNA sequence. The presence of telomerase will elongate the primers, leading to inner chain substitution followed by the release of the FITC fluorescence and the trapped doxorubicin. This molecular beacon could specifically distinguish tumor cells and normal cells based on telomerase activity, precisely release doxorubicin in response to telomerase activity in the tumor cells, and prevent toxicity to normal organs.